Diagnostic use of autoantibodies in myasthenia gravis

Autoimmunity

Volumn 43, Issue 5-6, 2010, Pages 371-379

  Leite, M Isabel ^a   Waters, Patrick ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

autoantibodies; cell based assay; methods of antibody detection; Myasthenia gravis; radioimmunoprecipitation assay

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; BUNGAROTOXIN RECEPTOR; CD20 ANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COBROTOXIN; CONNECTIN; ENZYME ANTIBODY; EUROPIUM; GREEN FLUORESCENT PROTEIN; HLA A1 ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; HLA DQ2 ANTIGEN; HLA DR ANTIGEN; HLA DR3 ANTIGEN; INTERFERON ANTIBODY; INTERLEUKIN 12 ANTIBODY; IODINE 125; MUSCLE ANTIBODY; MUSCLE SPECIFIC KINASE ANTIBODY; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV1.4 ANTIBODY; RITUXIMAB; RYANODINE; TITIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; CELL ASSAY; CHILDHOOD DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IMMUNOPRECIPITATION ASSAY; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PREGNANCY DISORDER; PROTEIN TARGETING; RADIOIMMUNOASSAY; RADIOIMMUNOPRECIPITATION; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SEROLOGY; THYMECTOMY; THYMOMA;

ADULT; AUTOANTIBODIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; HUMANS; IMMUNOLOGIC TESTS; MALE; MYASTHENIA GRAVIS; RADIOIMMUNOPRECIPITATION ASSAY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 77955897605     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903541208     Document Type: Review

References (59)

1. Aarli JA, Flood PR, Gilhus NE, Hofstad H, Matre R. Non-receptor striated muscle antibodies in sera from patients with myasthenia gravis. Monogr Allergy 1988;25:128-134.
2. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Arch Neurol 2005;62:442-446.
3. Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: Inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 1974;186:55-57.
4. Aharonov A, Abramsky O, Tarrab-Hazdai R, Fuchs S. Humoral antibodies to acetylcholine receptor in patients with myasthenia gravis. Lancet 1975;2:340-342.
5. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
6. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357-370.
7. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psych 1985;48:1246-1252.
8. Luther MA, Schoepfer R, Whiting P, Casey B, Blatt Y, Montal MS, Montal M, Linstrom J. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671. J Neurosci 1989;9:1082-1096.
9. Voltz R, Hohlfeld R, Fateh-Moghadam A, Witt TN, Wick M, Reimers C, Siegele B, Wekerle H. Myasthenia gravis: Measurement of anti-AChR autoantibodies using cell line TE671. Neurology 1991;41:1836-1838.
10. Somnier FE. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: The use of cell line TE671 as a source of AChR antigen. J Neuroimmunol 1994;51: 63-68.
11. Beeson D, Amar M, Bermudez I, Vincent A, Newsom-Davis J. Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the epsilon subunit. Neurosci Lett 1996;207:57-60.
12. Beeson D, Jacobson L, Newsom-Davis J, Vincent A. A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis. Neurology 1996;47: 1552-1555.
13. Ohta K, Fujinami A, Saida T, Nishimura M, Kuno S, Ohta M. Frequency of anti-AChR epsilon subunit-specific antibodies in MG. Autoimmunity 2003;36:151-154.
14. Buckley C, Vincent A. Autoimmune channelopathies. Nat Clin Pract Neurol 2005;1:22-33.
15. Hewer R, Matthews I, Chen S, McGrath V, Evans M, Roberts E, Nute S, Sanders J, Furmaniak J, Smith BR. A sensitive non-isotopic assay for acetylcholine receptor autoantibodies. Clin Chim Acta 2006;364:159-166.
16. Brooks EB, Pachner AR, Drachman DB, Kantor FS. A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: Positive results in "antibody-negative" myasthenia gravis. J Neuroimmunol 1990;28:83-93.
17. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
18. McConville J, Farrugia ME, BeesonD, KishoreU, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584. (Pubitemid 38391977)
19. Matthews I, Chen S, Hewer R, McGrath V, Furmaniak J, Rees Smith B. Muscle-specific receptor tyrosine kinase autoantibodies-a new immunoprecipitation assay. Clin Chim Acta 2004;348:95-99.
20. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008;65:913-919.
21. Hutchinson M,Waters P,McHugh J, Gorman G, O'Riordan S, Connolly S, Hager H, Yu P, Becker CM, Vincent A. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology 2008;71: 1291-1292.
22. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain 2008;131:1940-1952. (Pubitemid 351957451)
23. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
24. Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Different HLADR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics 1990;31:285-290.
25. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J Neuroimmunol 1993;47:115-122.
26. Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom- Davis J, Hoch W. Antibodies in myasthenia gravis and related disorders. Ann NY Acad Sci 2003;998:324-335.
27. Brueton LA, Huson SM, Cox PM, Shirley I, Thompson EM, Barnes PR, Price J, Newsom-Davis J, Vincent A. Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype. Am J Med Genet 2000;92:1-6.
28. Vincent A, Newland C, Brueton L, Beeson D, Riemersma S, Huson SM, Newsom-Davis J. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995;346:24-25.
29. Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol 2004;24:101-110.
30. Vincent A, Li Z, Hart A, Barrett-Jolley R, Yamamoto T, Burges J, Wray D, Byrne N, Molenaar P, Newsom-Davis J. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function. Ann NYAcad Sci 1993;681:529-538.
31. Palace J, Beeson D. The congenital myasthenic syndromes. J Neuroimmunol 2008;201-202:2-5.
32. Engel AG, Shen XM, Selcen D, Sine SM. Further, observations in congenital myasthenic syndromes. Ann NY Acad Sci 2008;1132:104-113.
33. Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psych 2003;74: 1105-1108.
34. Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 2005;65: 928-930.
35. Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Linkage of HLA to myasthenia gravis and genetic hetero: Geneity depending on anti-titin antibodies. Neurology 2001;57:1555-1560.
36. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology 2001;57:1579-1582.
37. Niks EH, Kuks JB, Roep BO, Haasnoot GW, Verduijn W, Ballieux BE, De Baets MH, Vincent A, Verschuuren JJ. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006;66: 1772-1774.
38. Leite MI, Strobel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibodynegative MG. Ann Neurol 2005;57:444-448.
39. Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N.Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171:893-905.
40. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, Bartoccioni E, Evoli A. Thymus changes in anti- MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536-538.
41. Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology 1978;28:266-272.
42. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci 2008;1132:305-314.
43. Vincent A, Newsom-Davis J, Newton P, BeckN. Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology 1983;33:1276-1282. (Pubitemid 13021187)
44. Farrugia ME, Melms A, Vincent A. Myasthenia gravis with MuSK antibodies. Pract Neurol 2005;5:356-359.
45. Bartoccioni E, Scuderi F, MinicuciGM, Marino M, Ciaraffa F, Evoli A. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology 2006;67:505-507.
46. Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E. Sustained response to Rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;201-202:90-94.
47. Mygland A, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, Gilhus NE, Aarli JA. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia. Arch Neurol 2000;57:527-531.
48. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82: 284-288.
49. Mygland A,Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Ann Neurol 1992;32:589-591.
50. Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, Suzuki N, Kuwana M. Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 2005;170:141-149.
51. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247:369-375.
52. Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Terayama Y, Suzuki N, Kuwana M. Classification of myasthenia gravis based on autoantibody status. Arch Neurol 2007;64: 1121-1124.
53. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin- 12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003;132:128-136.
54. Ohta M, Ohta K, Mori F, Itoh N, Nishitani H, Hayashi K. Improved radioassay of anti-acetylcholine receptor antibody: Application for the detection of extremely low antibody titers in sera from patients with myasthenia gravis. Clin Chem 1990; 36:911-913.
55. Ricny J, Simkova L, Vincent A. Determination of antiacetylcholine receptor antibodies in myasthenic patients by use of time-resolved fluorescence. Clin Chem 2002;48:549-554.
56. Furukawa S, Akazawa S, Furukawa Y, Kamo I, Satoyoshi E, Hayashi K. A practical enzyme immunoassay for anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1984;6:397-409.
57. Gotti C, Balestra B, Mantegazza R, Tzartos S, Moretti M, Clementi F. Detection of antibody classes and subpopulations in myasthenia gravis patients using a new nonradioactive enzyme immunoassay. Muscle Nerve 1997;20:800-808.
58. Franciotta D, Martino G, Brambilla E, Zardini E, Locatelli V, Bergami A, et al. TE671 cell-based ELISA for antiacetylcholine receptor antibody determination in myasthenia gravis. Clin Chem 1999;45:400-405.
59. Sanders J, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010;43:428-435.